News tagged with 'Troglitazone'

Pfizer has paid $750 million to resolve 35,000 claims over its diabetes drug Rezulin which was withdrawn in 2000 after it was linked to 63 or more deaths from liver damage.

West Virginia's state Supreme Court granted class-action status last week to 5,000 lawsuits filed over the recalled diabetes medication Rezulin. Reversing a decision made in 2001 by Raleigh County Judge John A. Hutchison, the high court concluded that class certification should have been granted two years ago based on

A New York jury last week found pharmaceutical maker Warner-Lambert liable in a multi-million dollar lawsuit filed over the withdrawn diabetes drug Rezulin. Attorneys representing Concepcion Morgado alleged Warner-Lambert, which was acquired by Pfizer Inc. in June 2000, misrepresented the drug and "omitted material in

A Texas jury ruled in favor of pharmaceutical giant Pfizer Inc. this week in a lawsuit filed over the now-banned diabetes medication Rezulin. Doris Brown, 63, died of liver and stomach complications in December 1998, eight months after beginning treatment with the drug. Brown's family filed suit against Warner-Lamb

A U.S. District Court judge in New York denied class action status for 4,000 plaintiffs suing Pfizer Inc. over the diabetes drug Rezulin. In his ruling, Judge Lewis A. Kaplan said that differing circumstances and injuries made a single class action lawsuit unfeasible. Plaintiffs' lawyers were seeking reimbursement fo

According to a story in yesterday's Los Angeles Times, Warner-Lambert Company executives intentionally concealed pertinent information regarding the dangers of the diabetes medication Rezulin. Documents obtained by the newspaper reportedly indicate that company officials delayed informing physicians and health regulat

An Oklahoma jury recently awarded $11.55 million to the family of a man who died after using the now banned diabetes drug Rezulin. Michael Wakefield, 41, died of liver failure in 1999 after using Rezulin for five weeks. In late 1997, Great Britain removed the drug from the market after several users were hospitalized

The fourth trial involving Rezulin maker Warner-Lambert began last week as jurors listened to opening statements from attorneys representing the family of a sixty-eight year old woman who died while awaiting a liver transplant. The lawsuit claims that Warner-Lambert, now owned by Pfizer, is responsible for the woman's

Last week a sixty-three-year-old woman settled her lawsuit against Pfizer, ending the second Rezulin case to go to trial. A Texas jury awarded $43 million in compensatory damages but Margarita Sanchez decided to settle with Rezulin's manufacturer rather than endure months of appeals. Sanchez claimed the diabetes drug

Warner-Lambert, a pharmaceutical company that recently merged with Pfizer Inc., is breathing a sigh of relief this week after winning the first trial involving complications associated with the diabetes drug Rezulin. The family of Norma Culberson, who died two years ago after taking Rezulin, was seeking $25 million in

Pfizer Inc., a top drug making company, settled a $20 million lawsuit out of court this week. The lawsuit is one of several against the leading drug maker resulting from the negative effects of Rezulin, a Pfizer diabetes drug pulled from the market last year after users reported liver complications. Pfizer settled

According to a Food and Drug Administration (FDA) study, physicians largely ignored FDA recommendations advising them to monitor liver enzymes in their patients taking Rezulin. In addition, it appears that doctors also dismissed liver damage advisories issued by Rezulin's manufacturer, Warner-Lambert Pharmaceuticals.

Rezulin, Warner-Lambert's drug for Type II diabetes, was first submitted to the FDA for review in 1996. Certain FDA investigators, including Dr. John L. Gueriguian, questioned Rezulin's effectiveness in controlling blood sugar levels. However, more troubling to Dr. Gueriguian were the deadly side effects that the dru

During the FDA clinical trials of Warner Lambert's proposed diabetes drug Rezulin, a senior FDA researcher raised questions about the drug's safety. He was fired shortly thereafter, and a Warner Lambert official characterized the firing as the removal of a "hurdle" to Rezulin's approval. The Los Angeles Times obtaine